Ajax loader
By using our website, you agree to our use of cookies as described in Cookie Policy.

Can't find what you're looking for?

 

Be sure to Sign in to see all available content.

 

If you don't have an account, Register here.

Search results for: Merck---Co.--Inc

NEW YORK-TIME 100 GALA/
RTX5XLHY
April 25, 2018
Kenneth Frazier, Chairman and CEO of Merck & CO., Inc., arrives for the TIME 100 Gala in Manhattan, New...
New York, UNITED STATES
Kenneth Frazier, Chairman and CEO of Merck & CO., Inc., arrives for the TIME 100 Gala in Manhattan
Kenneth Frazier, Chairman and CEO of Merck & CO., Inc., arrives for the TIME 100 Gala in Manhattan, New York, U.S., April 24, 2018. REUTERS/Shannon Stapleton
VENEZUELA-USA/CORPORATIONS
RTR4NYRC
February 02, 2015
A Chevrolet logo is seen on a car in Caracas January 30, 2015. At least 40 major U.S. companies have...
Caracas, Venezuela
Chevrolet logo is seen on a car in Caracas
A Chevrolet logo is seen on a car in Caracas January 30, 2015. At least 40 major U.S. companies have substantial exposure to Venezuela?s deepening economic crisis, and could collectively be forced to take billions of dollars of write downs, a Reuters analysis shows. The companies, all members of the S&P 500, and including some of the biggest names in Corporate America such as autos giant General Motors and drug maker Merck & Co Inc, together carry at least $11 billion of monetary assets in the Venezuelan currency, the bolivar, on their books. Picture taken January 30. To match Insight VENEZUELA-USA/CORPORATIONS REUTERS/Carlos Garcia Rawlins (VENEZUELA - Tags: BUSINESS TRANSPORT LOGO)
VENEZUELA-USA/CORPORATIONS
RTR4NYR2
February 02, 2015
The Chevrolet logo is seen at the top of a closed branch in Caracas January 30, 2015. At least 40 major...
Caracas, Venezuela
Chevrolet logo is seen at the top of a closed branch in Caracas
The Chevrolet logo is seen at the top of a closed branch in Caracas January 30, 2015. At least 40 major U.S. companies have substantial exposure to Venezuela?s deepening economic crisis, and could collectively be forced to take billions of dollars of write downs, a Reuters analysis shows. The companies, all members of the S&P 500, and including some of the biggest names in Corporate America such as autos giant General Motors and drug maker Merck & Co Inc, together carry at least $11 billion of monetary assets in the Venezuelan currency, the bolivar, on their books. Picture taken January 30. To match Insight VENEZUELA-USA/CORPORATIONS REUTERS/Carlos Garcia Rawlins (VENEZUELA - Tags: BUSINESS TRANSPORT LOGO)
HEALTH-SUMMIT/
RTXQKRV
November 10, 2009
Richard Clark, Chairman, President and Chief Executive Officer of Merck & Co., Inc., speaks at the Reuters...
New York, UNITED STATES
Richard Clark, Chairman, President and Chief Executive Officer of Merck & Co., Inc., speaks at the Reuters...
Richard Clark, Chairman, President and Chief Executive Officer of Merck & Co., Inc., speaks at the Reuters Health Summit in New York, November 10, 2009. REUTERS/Brendan McDermid (UNITED STATES HEALTH BUSINESS)
HEALTH-SUMMIT/
RTXQKRR
November 10, 2009
Richard Clark, Chairman, President and Chief Executive Officer of Merck & Co., Inc., speaks at the Reuters...
New York, UNITED STATES
Richard Clark, Chairman, President and Chief Executive Officer of Merck & Co., Inc., speaks at the Reuters...
Richard Clark, Chairman, President and Chief Executive Officer of Merck & Co., Inc., speaks at the Reuters Health Summit in New York, November 10, 2009. REUTERS/Brendan McDermid (UNITED STATES HEALTH BUSINESS)
HEALTH-SUMMIT/
RTXQKRP
November 10, 2009
Richard Clark, Chairman, President and Chief Executive Officer of Merck & Co., Inc., speaks at the Reuters...
New York, UNITED STATES
Richard Clark, Chairman, President and Chief Executive Officer of Merck & Co., Inc., speaks at the Reuters...
Richard Clark, Chairman, President and Chief Executive Officer of Merck & Co., Inc., speaks at the Reuters Health Summit in New York, November 10, 2009. REUTERS/Brendan McDermid (UNITED STATES HEALTH BUSINESS)
HEALTH-SUMMIT/
RTXQKRO
November 10, 2009
Richard Clark, Chairman, President and Chief Executive Officer of Merck & Co., Inc., speaks at the Reuters...
New York, UNITED STATES
Richard Clark, Chairman, President and Chief Executive Officer of Merck & Co., Inc., speaks at the Reuters...
Richard Clark, Chairman, President and Chief Executive Officer of Merck & Co., Inc., speaks at the Reuters Health Summit in New York, November 10, 2009. REUTERS/Brendan McDermid (UNITED STATES)
Business
Business
Merck Buys Schering-Plough For $41 Billion - 10 Mar 2009
16 PICTURES
SCHERINGPLOUGH-MERCK/
RTXCK41
March 09, 2009
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said...
Kenilworth, UNITED STATES
A view of the Schering-Plough campus in Kenilworth
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH)
SCHERINGPLOUGH-MERCK/
RTXCK3Y
March 09, 2009
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said...
Kenilworth, UNITED STATES
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. ÊREUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH)
SCHERINGPLOUGH-MERCK/
RTXCK2X
March 09, 2009
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would...
Linden, UNITED STATES
A view of the Merck & Co. campus in Linden, New Jersey
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH)
SCHERINGPLOUGH-MERCK/
RTXCK2R
March 09, 2009
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would...
Linden, UNITED STATES
A view of the Merck & Co. campus in Linden, New Jersey
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. ÊREUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH)
SCHERINGPLOUGH-MERCK/
RTXCK2M
March 09, 2009
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would...
Linden, UNITED STATES
A view of the Merck & Co. campus in Linden, New Jersey
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH)
SCHERINGPLOUGH-MERCK/
RTXCK2I
March 09, 2009
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would...
Linden, UNITED STATES
A view of the Merck & Co. campus in Linden, New Jersey
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH)
SCHERINGPLOUGH-MERCK/
RTXCK23
March 09, 2009
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would...
Linden, UNITED STATES
A view of the Merck & Co. campus in Linden, New Jersey
A view of the Merck & Co. campus in Linden, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH IMAGE OF THE DAY TOP PICTURE)
SCHERINGPLOUGH-MERCK/
RTXCK1V
March 09, 2009
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said...
Kenilworth, UNITED STATES
A view of the Schering-Plough campus in Kenilworth
A view of the Schering-Plough campus in Kenilworth, New Jersey March 9, 2009, after Merck & Co Inc said it would acquire Schering-Plough Corp in $41.1 billion deal, widening Merck's pipeline and diversifying its portfolio of medicines. REUTERS/Jeff Zelevansky (UNITED STATES BUSINESS HEALTH IMAGE OF THE DAY TOP PICTURE)
SCHERINGPLOUGH MERCK/
RTXCJUL
March 09, 2009
A sample of the drug Singulair made by Merck & Co. Inc. is seen in New York March 9, 2009. Merck & Co...
New York, UNITED STATES
A sample of the drug Singulair
A sample of the drug Singulair made by Merck & Co. Inc. is seen in New York March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Chip East (UNITED STATES HEALTH BUSINESS)
SCHERINGPLOUGH MERCK/
RTXCJUJ
March 09, 2009
A sample of the drug Singulair made by Merck & Co. Inc. is seen in New York March 9, 2009. Merck & Co...
New York, UNITED STATES
A sample of the drug Singulair
A sample of the drug Singulair made by Merck & Co. Inc. is seen in New York March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Chip East (UNITED STATES HEALTH BUSINESS)
SCHERINGPLOUGH MERCK/
RTXCJUH
March 09, 2009
A sample of the drug Nasonex made by the Schering Corporation is seen in New York, March 9, 2009. Merck...
New York, UNITED STATES
A sample of the drug Nasonex
A sample of the drug Nasonex made by the Schering Corporation is seen in New York, March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Chip East (UNITED STATES HEALTH)
SCHERINGPLOUGH MERCK/
RTXCJUF
March 09, 2009
A sample of the drug Proventil made by Schering Corporation is seen in New York March 9, 2009. Merck...
New York, UNITED STATES
A sample of the drug Proventil
A sample of the drug Proventil made by Schering Corporation is seen in New York March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Chip East (UNITED STATES HEALTH)
SCHERINGPLOUGH MERCK/
RTXCJUB
March 09, 2009
A sample of the drug Nasonex made by the Schering Corporation is seen in New York March 9, 2009. Merck...
New York, UNITED STATES
A sample of the drug Nasonex
A sample of the drug Nasonex made by the Schering Corporation is seen in New York March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Chip East (UNITED STATES HEALTH BUSINESS)
SCHERINGPLOUGH MERCK/
RTXCJU5
March 09, 2009
A sample of the drug Nasonex, made by the Schering Corporation, is seen in New York, March 9, 2009. ...
New York, UNITED STATES
A sample of the drug Nasonex made by the Schering Corporation
A sample of the drug Nasonex, made by the Schering Corporation, is seen in New York, March 9, 2009. Merck & Co Inc announced it would acquire Schering-Plough Corp for $41 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Chip East (UNITED STATES BUSINESS HEALTH)
SCHERINGPLOUGH-MERCK/
RTXCJPF
March 09, 2009
Richard Clark, Chairman and C.E.O. of Merck, speaks at the Reuters Health Summit in New York, in this...
New York, UNITED STATES
File photo of Richard Clark, Chairman and C.E.O. of Merck speaking at the Reuters Health Summit in New...
Richard Clark, Chairman and C.E.O. of Merck, speaks at the Reuters Health Summit in New York, in this file photo taken November 19, 2008. Merck & Co Inc. said on March 9, 2009 that it would acquire Schering-Plough Corp for $41.1 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Brendan McDermid/Files (UNITED STATES BUSINESS HEALTH SCI TECH HEADSHOT)
SCHERINGPLOUGH-MERCK/
RTXCJPA
March 09, 2009
Richard Clark, Chairman and C.E.O. of Merck, speaks at the Reuters Health Summit in New York, in this...
New York, UNITED STATES
File photo of Richard Clark, Chairman and C.E.O. of Merck speaking at the Reuters Health Summit in New...
Richard Clark, Chairman and C.E.O. of Merck, speaks at the Reuters Health Summit in New York, in this file image taken November 19, 2008. Merck & Co Inc. said on March 9, 2009 that it would acquire Schering-Plough Corp for $41.1 billion, uniting the makers of cholesterol drugs Zetia and Vytorin in the second megadeal for Big Pharma in weeks. REUTERS/Brendan McDermid/Files (UNITED STATES BUSINESS HEADSHOT HEALTH SCI TECH)
MERCK-BRAZIL/
RTR1PCC0
May 04, 2007
Brazil's President Luiz Inacio Lula da Silva speaks during a ceremony at Planalto Palace in Brasilia,...
Brasilia, Brazil
Brazil's President Lula da Silva speaks during ceremony at Planalto Palace in Brasilia
Brazil's President Luiz Inacio Lula da Silva speaks during a ceremony at Planalto Palace in Brasilia, May 4, 2007. Lula da Silva signed a decree on Friday authorizing Brazil to sidestep an AIDS drug patent held by Merck & Co. Inc. and import a cheaper generic version of the drug from India. REUTERS/Jamil Bittar (BRAZIL)
MERCK-BRAZIL/
RTR1PCBV
May 04, 2007
Brazil's President Luiz Inacio Lula da Silva (R) talks with Health Minister Jose Temporao during a ceremony...
Brasilia, Brazil
Brazil's President Lula da Silva talks with Health Minister Temporao during ceremony at Planalto Palace...
Brazil's President Luiz Inacio Lula da Silva (R) talks with Health Minister Jose Temporao during a ceremony at Planalto Palace in Brasilia, May 4, 2007. Lula da Silva signed a decree on Friday authorizing Brazil to sidestep an AIDS drug patent held by Merck & Co. Inc. and import a cheaper generic version of the drug from India. REUTERS/Jamil Bittar (BRAZIL)
MERCK-BRAZIL/
RTR1PCBT
May 04, 2007
Brazil's President Luiz Inacio Lula da Silva speaks beside Health Minister Jose Temporao (R) during a...
Brasilia, Brazil
Brazil's President Lula da Silva speaks during ceremony at Planalto Palace in Brasilia
Brazil's President Luiz Inacio Lula da Silva speaks beside Health Minister Jose Temporao (R) during a ceremony at Planalto Palace in Brasilia, May 4, 2007. Lula da Silva signed a decree on Friday authorizing Brazil to sidestep an AIDS drug patent held by Merck & Co. Inc. and import a cheaper generic version of the drug from India. REUTERS/Jamil Bittar (BRAZIL)
THAILAND-DRUGS/
RTR1MI36
February 17, 2007
Efavirenz, a HIV-AIDS drug by Merck & Co., is photographed at the Phrabat Nampu Temple in Thailand's...
Bangkok, Thailand
Efavirenz, a HIV-AIDS drug by Merck & Co., is photographed at the Phrabat Nampu Temple in Thailand's...
Efavirenz, a HIV-AIDS drug by Merck & Co., is photographed at the Phrabat Nampu Temple in Thailand's Lopburi Province February 17, 2007. MercK & Co. announced on Thursday price cuts for Efavirenz, in poor countries and those hard hit by the disease, including Thailand, which plans to make a copycat version of the medicine. REUTERS/Adrees Latif (THAILAND)
SUMMIT HEALTH
RTR1J5Q6
November 08, 2006
Richard Clark, CEO and president of Merck & Co. Inc., talks during the Reuters Health Summit in New York...
New York, UNITED STATES
Richard Clark, CEO and president of Merck & Co. Inc., talks during the Reuters Health Summit in New York...
Richard Clark, CEO and president of Merck & Co. Inc., talks during the Reuters Health Summit in New York November 8, 2006. REUTERS/Brendan McDermid (UNITED STATES)
SUMMIT HEALTH
RTR1J5OF
November 08, 2006
Richard Clark, CEO and president of Merck & Co. Inc., talks during the Reuters Health Summit in New York...
New York, UNITED STATES
Richard Clark, CEO and president of Merck & Co. Inc., talks during the Reuters Health Summit in New York...
Richard Clark, CEO and president of Merck & Co. Inc., talks during the Reuters Health Summit in New York November 8, 2006. REUTERS/Brendan McDermid (UNITED STATES)
SUMMIT HEALTH
RTR1J5OE
November 08, 2006
Richard Clark, CEO and president of Merck & Co. Inc., talks during the Reuters Health Summit in New York...
New York, UNITED STATES
Richard Clark, CEO and president of Merck & Co. Inc., talks during the Reuters Health Summit in New York...
Richard Clark, CEO and president of Merck & Co. Inc., talks during the Reuters Health Summit in New York November 8, 2006. REUTERS/Brendan McDermid (UNITED STATES)
SUMMIT HEALTH
RTR1J5OB
November 08, 2006
Richard Clark, CEO and president of Merck & Co. Inc., listens to questions during the Reuters Health...
New York, UNITED STATES
Richard Clark, CEO and president of Merck & Co. Inc., listens to questions during the Reuters Health...
Richard Clark, CEO and president of Merck & Co. Inc., listens to questions during the Reuters Health Summit in New York November 8, 2006. REUTERS/Brendan McDermid (UNITED STATES)
SINGAPORE ECONOMY DRUGS
RTR1B5VQ
December 16, 2005
A scientist works in GlaxoSmithKline's plant in Singapore December 16, 2005. Singapore has lured some...
Singapore, Singapore
Scientist works in GlaxoSmithKline's plant in Singapore
A scientist works in GlaxoSmithKline's plant in Singapore December 16, 2005. Singapore has lured some of the biggest names in the drugs industry -- from Pfizer Inc. of the U.S. to Switzerland's Novartis -- in its quest for new industries to help drive economic growth. Once heavily dependent on electronics exports such as semiconductors and disk drives, the island now earns an increasing amount by producing ingredients for GlaxoSmithKline's antibiotics line and Merck & Co.'s cholesterol-reducers. REUTERS/Luis Enrique Ascui
SINGAPORE DRUGS ECONOMY
RTR1B54R
December 16, 2005
A scientist works in GlaxoSmithKline's plant in Singapore December 16, 2005. Singapore has lured some...
Singapore, Singapore
Scientist works in GlaxoSmithKline's plant in Singapore
A scientist works in GlaxoSmithKline's plant in Singapore December 16, 2005. Singapore has lured some of the biggest names in the drugs industry -- from Pfizer Inc. of the U.S. to Switzerland's Novartis -- in its quest for new industries to help drive economic growth. Once heavily dependent on electronics exports such as semiconductors and disk drives, the island now earns an increasing amount by producing ingredients for GlaxoSmithKline's antibiotics line and Merck & Co.'s cholesterol-reducers. REUTERS/Luis Enrique Ascui
ZOCOR
RTXO0QH
November 28, 2005
A 20mg dose of Zocor, the Merck & Co. Inc cholesterol fighting drug, is shown in a pharmacy in Westfield,...
Rahway, USA
A 20mg dose of Zocor, the Merck & Co. Inc cholesterol fighting drug, is shown in a pharmacy in Westf.....
A 20mg dose of Zocor, the Merck & Co. Inc cholesterol fighting drug, is shown in a pharmacy in Westfield, New Jersey, November 28, 2005. Merck on Monday said it will cut 7,000 jobs and close five plants to save up to $4 billion in costs by 2010, but shares fell on disappointment at the scope of the measures and their limited ability to help earnings next year.
ZOCOR
RTXO0QG
November 28, 2005
Bottles of Zocor, the Merck & Co. Inc cholesterol fighting drug, are shown in a pharmacy in Westfield,...
Rahway, USA
Bottles of Zocor, the Merck & Co. Inc cholesterol fighting drug, are shown in a pharmacy in Westfiel.....
Bottles of Zocor, the Merck & Co. Inc cholesterol fighting drug, are shown in a pharmacy in Westfield, New Jersey, November 28, 2005. Merck & Co. Inc. on Monday said it will cut 7,000 jobs and close five plants to save up to $4 billion in costs by 2010, but shares fell on disappointment at the scope of the measures and their limited ability to help earnings next year. Merck said its profit next year will fall at least 4.4 percent, hurt by the mid-year patent expiration in the United States on Zocor. Zocor had third-quarter U.S. sales of $770 million, but they are expected to tumble once generic forms of the drug become available, hurting overall company profit margins.
HEALTH MERCK
RTR1BR1U
November 28, 2005
A 20mg dose of Zocor, the Merck & Co. Inc cholesterol fighting drug, is shown in a pharmacy in Westfield,...
Rahway, UNITED STATES
A 20mg dose of Zocor is shown in a pharmacy in Westfield
A 20mg dose of Zocor, the Merck & Co. Inc cholesterol fighting drug, is shown in a pharmacy in Westfield, New Jersey, November 28, 2005. Merck on Monday said it will cut 7,000 jobs and close five plants to save up to $4 billion in costs by 2010, but shares fell on disappointment at the scope of the measures and their limited ability to help earnings next year. REUTERS/Jeff Zelevansky
HEALTH MERCK
RTR1BQXM
November 28, 2005
Bottles of Zocor, the Merck & Co. Inc cholesterol fighting drug, are shown in a pharmacy in Westfield,...
Westfield, UNITED STATES
Bottles of cholesterol drug Zocor are shown as Merck announces plans to cut jobs and close factories
Bottles of Zocor, the Merck & Co. Inc cholesterol fighting drug, are shown in a pharmacy in Westfield, New Jersey, November 28, 2005. Merck & Co. Inc. on Monday said it will cut 7,000 jobs and close five plants to save up to $4 billion in costs by 2010, but shares fell on disappointment at the scope of the measures and their limited ability to help earnings next year. Merck said its profit next year will fall at least 4.4 percent, hurt by the mid-year patent expiration in the United States on Zocor. Zocor had third-quarter U.S. sales of $770 million, but they are expected to tumble once generic forms of the drug become available, hurting overall company profit margins. REUTERS/Jeff Zelevansky
VIOXX
RTRG2X1
November 18, 2004
Merck Chief Executive Raymond Gilmartin (R) looks toward Dr. David Graham, Associate Director for Science,...
Washington, UNITED STATES
Merck Chairman Gilmartin and Dr. David Graham listen to Vioxx hearing.
Merck Chief Executive Raymond Gilmartin (R) looks toward Dr. David Graham, Associate Director for Science, Office of Drug Safety at the Food and Drug Administration, during a hearing of Senate Finance Committee about the drug Vioxx, on Capitol Hill November 18, 2004. Graham earlier said FDA's handling of Merck & Co Inc.'s withdrawn painkiller Vioxx, is a "profound regulatory failure" by an agency "incapable of protecting America" from another dangerous drug. REUTERS/Kevin Lamarque KL/HB
VIOXX
RTRG2LK
November 18, 2004
Dr. David Graham, Associate Director for Science, Office of Drug Safety at the Food and Drug Administration,...
Washington, UNITED STATES
FDAs Dr David Graham speaks at Vioxx probe.
Dr. David Graham, Associate Director for Science, Office of Drug Safety at the Food and Drug Administration, testifies before the Senate Finance Committee on Capitol Hill, November 18, 2004. Graham said FDA's handling of Merck & Co Inc.'s withdrawn painkiller Vioxx, is a "profound regulatory failure" by an agency "incapable of protecting America" from another dangerous drug. REUTERS/Kevin Lamarque
VIOXX
RTRG2GC
November 18, 2004
Dr. David Graham, Associate Director for Science, Office of Drug Safety at the Food and Drug Administration...
Washington, UNITED STATES
Dr David Graham and Dr Psaty listen at Vioxx probe.
Dr. David Graham, Associate Director for Science, Office of Drug Safety at the Food and Drug Administration (R) and Dr. Bruce Psaty, Professor of Medicine at the University of Washington, listen to testimony on the safety of Vioxx during a hearing before the Senate Finance Committee on Capitol Hill, November 18, 2004. Graham said FDA's handling of Merck & Co Inc.'s withdrawn painkiller Vioxx, is a "profound regulatory failure" by an agency "incapable of protecting America" from another dangerous drug. REUTERS/Kevin Lamarque KL/HB
VIOXX
RTRG2EK
November 18, 2004
Dr. David Graham, Associate Director for Science, Office of Drug Safety at the Food and Drug Administration,...
Washington, UNITED STATES
FDAs Dr David Graham speaks at Vioxx probe.
Dr. David Graham, Associate Director for Science, Office of Drug Safety at the Food and Drug Administration, testifies before the Senate Finance Committee on Capitol Hill, November 18, 2004. Graham said FDA's handling of Merck & Co Inc.'s withdrawn painkiller Vioxx, is a "profound regulatory failure" by an agency "incapable of protecting America" from another dangerous drug. REUTERS/Kevin Lamarque
VIOXX
RTRG2E9
November 18, 2004
Merck Chief Executive Raymond Gilmartin listens to the testimony of Food and Drug Administration's Dr....
Washington, UNITED STATES
Merck Chairman Gilmartin listens to Dr David Graham of the FDA.
Merck Chief Executive Raymond Gilmartin listens to the testimony of Food and Drug Administration's Dr. David Graham in front of the Senate Finance Committee on Capitol Hill, November 18, 2004. Graham said FDA's handling of Merck & Co Inc.'s withdrawn painkiller Vioxx, is a "profound regulatory failure" by an agency "incapable of protecting America" from another dangerous drug. REUTERS/Kevin Lamarque KL/HB
HEALTH CDC
RTR7D8B
July 08, 2002
The Merck and Company Pharmaceutical and Services building in Duluth,
Georgia, July 8, 2002. Merck &...
Duluth, United States of America
SIGN AT MERCK PHARMACEUTICAL AND SERVICES COMPANY IN DULUTH GEORGIA.
The Merck and Company Pharmaceutical and Services building in Duluth,
Georgia, July 8, 2002. Merck & Co. Inc. reported its Medco pharmacy benefits
management business booked $14 billion in revenue it never collected, but
the drugmaker said on Monday it would go ahead with Medco's planned public
offering as early as this week. Merck's revelation initially rattled world
currency and stock markets on investor concerns the announcement marked
another accounting scandal. But the accounting treatment had no effect on
net income, and the company's shares fell slightly. REUTERS/Tami Chappell

TLC/HB
HEALTH CDC
RTR7D77
July 08, 2002
The Merck and Company Pharmaceutical and Services building in Duluth,
Georgia, July 8, 2002. Merck &...
Duluth, United States of America
SIGN AT MERCK PHARMACEUTICAL AND SERVICES COMPANY IN DULUTH GEORGIA.
The Merck and Company Pharmaceutical and Services building in Duluth,
Georgia, July 8, 2002. Merck & Co. Inc. reported its Medco pharmacy benefits
management business booked $14 billion in revenue it never collected, but
the drugmaker said on Monday it would go ahead with Medco's planned public
offering as early as this week. Merck's revelation initially rattled world
currency and stock markets on investor concerns the announcement marked
another accounting scandal. But the accounting treatment had no effect on
net income, and the company's shares fell slightly. REUTERS/Tami Chappell

TLC/HB
Sort by
Display
Items per page
Page
of 1